Compounds and methods for treatment of chemotherapy-induced anemia
The invention relates to methods and compounds for treating chemotherapy-induced anemia. In particular, methods for treating chemotherapy-induced anemia in subjects refractory to treatment with recombinant human erythropoietin are encompassed herein.
1. A method for treating chemotherapy-induced anemia in a subject refractory to recombinant human EPO therapy, the method comprising the steps of determining whether the subject is refractory to recombinant human EPO therapy and administering to the subject an effective amount of an agent that inhibits hypoxia inducible factor (HIF) hydroxylase activity.
2. The method of claim 1 , wherein the subject is undergoing chemotherapy.
3. The method of claim 1 , wherein the subject has undergone chemotherapy.
4. The method of claim 1 , wherein the subject is expected to undergo chemotherapy.
5. The method of claim 1 , wherein the chemotherapy comprises administration of a chemotherapeutic selected from the group consisting of: an alkylating agent; a nitrosoureas;
an antimetabolite; an anthracyclines; a topoisomerase II inhibitor; a mitotic inhibitor; an anti-estrogen; a progestin; an aromatase inhibitor; an anti-androgen; an LHRH agonist; a corticosteroid hormone; a DNA alkylating agent; a taxane; a vince alkaloid; and a microtubule poison.
6. The method of claim 1 , wherein the chemotherapeutic is selected from the group consisting of busulfan, cisplatin, carboplatin, chlorambucil, cyclophosphamide, ifosfamide, dacarbazine (DTIC), mechlorethamine (nitrogen mustard), melphalan, temozolomide, carmustine (BCNU), lomustine (CCNU), 5-fluorouracil, capecitabine, 6-mercaptopurine, methotrexate, gemcitabine, cytarabine (ara-C), fludarabine, pemetrexed, daunorubicin, doxorubicin (Adriamycin), epirubicin, idarubicin, mitoxantrone, topotecan, irinotecan, etoposide (VP-16), teniposide, paclitaxel, docetaxel, vinbiastine, vincristine, vinorelbine, prednisone, dexamethasone, L-asparaginase, dactinomycin, thalidomide, tretinoin, imatinib (Gleevec), gefitinib (Iressa), erlotinib (Tarceva), rituximab (Rituxan), bevacizumab (Avastin), tamoxifen, fulvestrant, anastrozole, exemestane, letrozole, megestrol acetate, bicalutamide, flutamide, leuprolide, and goserelin.
7. The method of claim 1 , wherein the agent is a 2-oxoglutarate mimetic.
8. The method of claim 1 , wherein the agent is administered orally, systemically, intravenously, or by injection.